Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,038 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Responsiveness and meaningful change thresholds of the Living with Pulmonary Fibrosis (L-PF) questionnaire Dyspnoea and Cough scores in patients with progressive fibrosing interstitial lung diseases.
Swigris JJ, Bushnell DM, Rohr K, Mueller H, Baldwin M, Inoue Y. Swigris JJ, et al. Among authors: baldwin m. BMJ Open Respir Res. 2022 Mar;9(1):e001167. doi: 10.1136/bmjresp-2021-001167. BMJ Open Respir Res. 2022. PMID: 35241434 Free PMC article. Clinical Trial.
The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases.
Birring SS, Bushnell DM, Baldwin M, Mueller H, Male N, Rohr KB, Inoue Y. Birring SS, et al. Among authors: baldwin m. Eur Respir J. 2022 Jun 2;59(6):2101790. doi: 10.1183/13993003.01790-2021. Print 2022 Jun. Eur Respir J. 2022. PMID: 34764181 Free PMC article.
The Burden of Progressive-Fibrosing Interstitial Lung Diseases.
Cottin V, Teague R, Nicholson L, Langham S, Baldwin M. Cottin V, et al. Among authors: baldwin m. Front Med (Lausanne). 2022 Feb 1;9:799912. doi: 10.3389/fmed.2022.799912. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35178411 Free PMC article. Review.
Developing a conceptual model of symptoms and impacts in progressive fibrosing interstitial lung disease to evaluate patient-reported outcome measures.
Wijsenbeek M, Molina-Molina M, Chassany O, Fox J, Galvin L, Geissler K, Hammitt KM, Kreuter M, Moua T, O'Brien EC, Slagle AF, Krasnow A, Reaney M, Baldwin M, Male N, Rohr KB, Swigris J, Antoniou K. Wijsenbeek M, et al. Among authors: baldwin m. ERJ Open Res. 2022 May 3;8(2):00681-2021. doi: 10.1183/23120541.00681-2021. eCollection 2022 Apr. ERJ Open Res. 2022. PMID: 35509443 Free PMC article.
Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy.
Selya-Hammer C, Gonzalez-Rojas Guix N, Baldwin M, Ternouth A, Miravitlles M, Rutten-van Mölken M, Goosens LM, Buyukkaramikli N, Acciai V. Selya-Hammer C, et al. Among authors: baldwin m. Ther Adv Respir Dis. 2016 Oct;10(5):391-401. doi: 10.1177/1753465816657272. Epub 2016 Jul 12. Ther Adv Respir Dis. 2016. PMID: 27405723 Free PMC article.
1,038 results